Although the standard therapies for GCA and GPA are not designed to directly target CD8+ T cells, studying the effects of these treatments on CD8+ T cell function could aid in unraveling their role in these diseases. The gene discussed is CD8A; the disease is granulomatosis with polyangiitis.